Nodar, Inc. specializes in manufacturing advanced sensors for various transportation modes, including cars, trucks, drones, ships, trains, and aircraft. The company offers innovative LiDAR technology and a 3D stereo vision system called Nodar Longbow, which is designed to enhance the capabilities of autonomous vehicles. Founded in 2018 and based in Boston, Massachusetts, Nodar aims to provide a cost-effective and high-performance solution for the automotive, marine, and railway industries. Their products, including the Hammerhead system, utilize off-the-shelf cameras to deliver precise depth sensing, targeting applications for level 3 and level 4 autonomous vehicles. This technology supports functions such as collision warning, path planning, and automatic emergency braking, contributing to improved safety and performance in the automotive sector.
Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.
Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.
Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.
Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.
Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.
Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company dedicated to developing novel, non-opioid, and non-addictive therapies for chronic pain management. Founded in 2013 and based in Boston, Massachusetts, the company’s product pipeline includes CNTX-4975, currently undergoing Phase III trials for knee osteoarthritis pain and Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials for various chronic pain conditions, while CNTX-6970 targets inflammatory pain and CNTX-2022, a high-concentration topical gel formulation of lidocaine, is also in Phase I trials for superficial musculoskeletal pain and related conditions. Furthermore, CNTX-6016 is a pre-clinical candidate aimed at treating chronic neuropathic pain. Centrexion Therapeutics is committed to addressing the unmet medical needs in chronic pain treatment by focusing on safety and efficacy.
Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.
Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.
Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.
Fam's mission is to build products that revolutionize the way teens and millennials communicate. They believe in a calculated combination of live group video and group chat messaging to execute this. It is the world’s first group video chat app for iMessage, with over 7 million users. Their app instantly connects with the family and friends closest to its user through group video calling, right from their iPhone, and Android text message app.
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.
Barkly is an endpoint protection platform focused on safeguarding users from contemporary cyber threats. The platform employs a patented method that integrates responsive machine learning with runtime behavior analysis to effectively block various types of attacks such as file-based, fileless, and exploit breaches. Barkly's technology offers deep CPU-level visibility and operates without compromising system performance, ensuring comprehensive protection against a wide range of cyber threats, including exploits, scripts, executables, and ransomware. The platform is designed to deliver robust security while minimizing false positives and simplifying management for users.
Docent Health's mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.
Docent Health's mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.
Sundar, Inc. operates a curated digital platform that facilitates material discovery and supplier sourcing for the apparel and design industries. Founded in 2013 and based in Boston, Massachusetts, the company connects creative professionals with quality materials and qualified vendors globally. By offering centralized digital catalogs, advanced search features, and data-driven recommendations, Sundar enhances the sourcing process for both emerging and established designers. The platform promotes collaboration between material research, design, and production teams, streamlining the discovery and sampling of textiles and raw materials. Recognized with awards from prestigious organizations and featured in notable publications, Sundar has established itself as a key player in modernizing the apparel supply chain, which has traditionally been antiquated and opaque. The company has received backing from top venture capital firms and has roots in respected incubators such as MIT and Techstars.
Acquia Inc. is a provider of cloud-based solutions designed to build, deliver, and optimize digital experiences for various sectors, including government, education, consumer brands, and financial services. Founded in 2007 and headquartered in Boston, Massachusetts, Acquia offers a range of products, including Acquia Cloud, a Platform-as-a-Service for managing Drupal websites, and Acquia Lift, which facilitates the creation of brand and campaign sites. Other notable solutions include Acquia Content Hub for content distribution, Acquia Journey for customer journey mapping, and Acquia Digital Asset Manager for centralizing creative assets. The company's platform enables organizations to enhance customer engagement through cross-channel, contextually relevant digital experiences, supporting clients like the BBC, Nasdaq, and Stanford University in accelerating their time to market. Acquia also offers technical support and services, ensuring clients can effectively implement and maintain their digital strategies.
Rhythm Metabolic
Series A in 2015
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
Barkly is an endpoint protection platform focused on safeguarding users from contemporary cyber threats. The platform employs a patented method that integrates responsive machine learning with runtime behavior analysis to effectively block various types of attacks such as file-based, fileless, and exploit breaches. Barkly's technology offers deep CPU-level visibility and operates without compromising system performance, ensuring comprehensive protection against a wide range of cyber threats, including exploits, scripts, executables, and ransomware. The platform is designed to deliver robust security while minimizing false positives and simplifying management for users.
Acquia Inc. is a provider of cloud-based solutions designed to build, deliver, and optimize digital experiences for various sectors, including government, education, consumer brands, and financial services. Founded in 2007 and headquartered in Boston, Massachusetts, Acquia offers a range of products, including Acquia Cloud, a Platform-as-a-Service for managing Drupal websites, and Acquia Lift, which facilitates the creation of brand and campaign sites. Other notable solutions include Acquia Content Hub for content distribution, Acquia Journey for customer journey mapping, and Acquia Digital Asset Manager for centralizing creative assets. The company's platform enables organizations to enhance customer engagement through cross-channel, contextually relevant digital experiences, supporting clients like the BBC, Nasdaq, and Stanford University in accelerating their time to market. Acquia also offers technical support and services, ensuring clients can effectively implement and maintain their digital strategies.
Influitive Corporation specializes in advocate marketing software solutions tailored for business-to-business (B2B) software and technology firms globally. Its primary product, AdvocateHub, enables companies to create advocate communities that engage customers, partners, and employees in marketing activities such as referrals, reference calls, and product reviews. This platform helps businesses harness customer enthusiasm to enhance their marketing and sales initiatives. AdvocateHub integrates with Salesforce, allowing for seamless tracking of customer engagement. Additionally, Influitive offers consulting services that include coaching and training to assist companies in implementing effective advocate marketing strategies. The AdvocateHub software is accessible through a web portal, with integration options for client websites and mobile access via the Maven app. Founded in 2010 and headquartered in Toronto, Canada, Influitive also has offices in Menlo Park, California, and Boston, Massachusetts.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
Influitive Corporation specializes in advocate marketing software solutions tailored for business-to-business (B2B) software and technology firms globally. Its primary product, AdvocateHub, enables companies to create advocate communities that engage customers, partners, and employees in marketing activities such as referrals, reference calls, and product reviews. This platform helps businesses harness customer enthusiasm to enhance their marketing and sales initiatives. AdvocateHub integrates with Salesforce, allowing for seamless tracking of customer engagement. Additionally, Influitive offers consulting services that include coaching and training to assist companies in implementing effective advocate marketing strategies. The AdvocateHub software is accessible through a web portal, with integration options for client websites and mobile access via the Maven app. Founded in 2010 and headquartered in Toronto, Canada, Influitive also has offices in Menlo Park, California, and Boston, Massachusetts.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
Eventup, Inc. provides online marketplace for booking venues for events. The company offers venues that include homes, apartments, condos, lofts, hotels, boats, yachts, galleries/museums, and other spaces for various events, such as weddings, parties, concerts, gatherings, and corporate celebrations. Eventup, Inc. was founded in 2011 and is based in Santa Monica, California. It has operations in Los Angeles, New York, San Francisco, Chicago, Miami, Boston, Atlanta, and Washington, D.C. As of June 28, 2018, Eventup, Inc. operates as a subsidiary of Gather Technologies, Inc.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
As of March 2007, PolyServe, Inc. was acquired by Hewlett-Packard Co. PolyServe, Inc. provides software that consolidates servers and storage into manageable, scalable, and available database and file serving utilities. It offers Database Utility for SQL server consolidation, Oracle, Oracle RAC, and DB2; File Serving Utility for high performance scalable NAS, Windows file and print, Web and application clusters, and Oracle. The company's products are distributed through a network of international distributors and direct sales force. The company has strategic partnerships with HP, Microsoft, IBM, Dell, and Novell. The company was incorporated in 1999 and is headquartered in Beaverton, Oregon with additional offices in Atlanta, Boston, Chicago, Houston, Minneapolis, New York, Washington, District of Columbia, San Francisco, and London.
As of March 2007, PolyServe, Inc. was acquired by Hewlett-Packard Co. PolyServe, Inc. provides software that consolidates servers and storage into manageable, scalable, and available database and file serving utilities. It offers Database Utility for SQL server consolidation, Oracle, Oracle RAC, and DB2; File Serving Utility for high performance scalable NAS, Windows file and print, Web and application clusters, and Oracle. The company's products are distributed through a network of international distributors and direct sales force. The company has strategic partnerships with HP, Microsoft, IBM, Dell, and Novell. The company was incorporated in 1999 and is headquartered in Beaverton, Oregon with additional offices in Atlanta, Boston, Chicago, Houston, Minneapolis, New York, Washington, District of Columbia, San Francisco, and London.
As of March 2007, PolyServe, Inc. was acquired by Hewlett-Packard Co. PolyServe, Inc. provides software that consolidates servers and storage into manageable, scalable, and available database and file serving utilities. It offers Database Utility for SQL server consolidation, Oracle, Oracle RAC, and DB2; File Serving Utility for high performance scalable NAS, Windows file and print, Web and application clusters, and Oracle. The company's products are distributed through a network of international distributors and direct sales force. The company has strategic partnerships with HP, Microsoft, IBM, Dell, and Novell. The company was incorporated in 1999 and is headquartered in Beaverton, Oregon with additional offices in Atlanta, Boston, Chicago, Houston, Minneapolis, New York, Washington, District of Columbia, San Francisco, and London.
Datalogix® is the industry-recognized leader at connecting digital media and offline purchasing data. We help more than half of the top 100 consumer marketers increase the effectiveness and measurability of their advertising. DLX Platform®, encompasses over $1 trillion in consumer spending and powers campaigns for more than 75% of online media companies. DLX ROI® is rapidly becoming the industry standard for measuring offline sales lift for digital media. Datalogix also offers predictive analytics for Direct Mail, and integrated media solutions via the DLX Net. Our expertise spans the major consumer segments, including Retail, CPG, Automotive, Telecom, Travel and Financial Services. We are based in Colorado, with offices in New York City, San Francisco, Boston, Chicago, Detroit, and London.
Vertex Pharmaceuticals is a biotechnology company dedicated to the discovery and development of small-molecule drugs aimed at treating serious diseases. The company's primary focus is on areas such as viral diseases, cystic fibrosis, inflammation, autoimmune disorders, cancer, and pain management. Vertex is known for its key cystic fibrosis therapies, including Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, which are considered the standard of care worldwide. Additionally, the company has expanded its portfolio to include Casgevy, a gene-editing therapy for beta thalassemia and sickle cell disease. Vertex is also exploring innovative treatments, such as small-molecule inhibitors for acute and chronic pain that are non-opioid, as well as potential therapies targeting kidney diseases related to APOL1. Through its collaborative and independent commercialization strategies, Vertex aims to bring effective solutions to the market for patients with serious health conditions.